The CRA Shortage Isn't a Mystery. It's a Warning Sign.

The CRA Shortage Isn't a Mystery. It's a Warning Sign. If you're a Clinical Research Associate, you already know the feeling: your calendar is overloaded, your travel schedule never lets up, and every time a colleague leaves, their workload lands on your desk too. What you might not know is just how widespread, and how well documented, this problem really is across the industry. We dug into the data. Here's what it shows, and why it's exactly the kind of problem a union exists to fix. A shortage that keeps getting worse at the top. The clinical research industry has been short on CRAs for over a decade. Back in 2015, industry groups were already flagging thousands of unfilled CRA positions in the U.S., warning of a hiring cycle with no end in sight. That warning went unheeded. Recent surveys show 88% of industry professionals still report a CRA shortage today, with turnover rates as high as 30% in some regions. What's changed is where the shortage bites hardest. It's no longer primarily a problem for people just starting out. It's the experienced CRAs who are hardest to find and hardest to keep, a shift that accelerated during the pandemic and never reversed. Part of the blame lands on a rigid requirement used across the industry: most employers demand a minimum of two years of experience before they'll even consider a CRA for a role. That bar exists more as tradition than as evidence. One study of 579 CRAs across a global CRO found no meaningful performance difference tied to seniority or years on the job. Meanwhile, academic and cancer research centers are being hit hardest of all. A 2023 review found 95% of major cancer centers reporting staffing shortages that were actively delaying trials, as site based staff get poached by better paying industry roles. Turnover is expensive, and it's not just a line item Every time a CRA walks out the door, someone has to pay for it: recruiting, training, retraining, and the inevitable slowdown while a new person gets up to speed. Sites feel it too. Building trust with a new monitor takes time, and it wears on site staff to keep re explaining documents a previous CRA already reviewed. There is modest improvement to report: the median total turnover rate for CRA roles dropped from 30% in 2022 to 22% in 2024, and average time to fill an open role fell from 1.9 months to 1.6 months over the same period. Progress, but still a heavy, ongoing cost. The consequences aren't just administrative friction. High turnover has been linked to real quality and compliance risk: a late adverse event report, a missed data point, an oversight that slips through because the person who should have caught it left the study. That's not a knock on any individual CRA. It's what happens when an industry treats staffing instability as background noise instead of a structural problem. The real reason CRAs are leaving Ask CRAs why they leave, and the answer isn't complicated: 74% point to higher salaries elsewhere, 45% cite better growth opportunities, and 29% cite burnout. And when you look at the actual workload, burnout stops being a mystery. CRAs report spending 165 hours a month on the job: 41% on site monitoring, 22% off site monitoring, 18% traveling to meetings and visits, and the rest on administrative work and training. Depending on whether you work for a sponsor or a CRO, that mix shifts, but the total burden doesn't. Regulators have taken notice too. Both the FDA and EMA have raised concerns that overloaded CRAs create real risk to study oversight and data integrity, concerns made worse by the fact that, remarkably, there's still no standardized benchmark anywhere in the industry for what a reasonable CRA workload should even look like. Sponsors and CROs are in effect flying blind on the very workload driving their staffing crisis. The industry's response so far: incremental, not structural To its credit, the industry has started experimenting with fixes: remote and regionalized monitoring to cut down travel, homegrown training pipelines that build talent from within, and rising pay, with North American CRA salaries climbing 10 to 15 percent in just the past few years. Among organizations that have made changes, 65% point to flexible work schedules and 55% point to higher salaries as their top retention strategies. Technology has shifted some of the work too: 76% of CRAs did most of their monitoring visits remotely in 2020, up from just 18% in 2019, and by 2021, 97% of sponsors were using software to review source data remotely. These changes help. But notice what they have in common: they are driven entirely by employers, offered voluntarily, and applied inconsistently from one company to the next. There's no seat at the table for CRAs themselves in deciding what a reasonable workload means, what fair pay looks like, or how staffing decisions get made when a trial is understaffed and deadlines don't move. How The CRA Union solves this issue Every pain point in this data, from the workload to the pay gaps to the arbitrary experience requirements to the total absence of any real workload standard to the turnover nobody wants to fix at the root, points to the same conclusion: individual CRAs negotiating alone can't solve a problem this deep and this widespread. Collective bargaining can. The CRA Union gives CRAs a formal voice in the decisions currently made about them, not with them: safe and sustainable workload standards, transparent and equitable pay, real career paths instead of burnout as the default exit ramp, and a say in how staffing models affect the people actually doing the work. The industry has spent a decade managing this crisis instead of solving it. It's time CRAs had a real say in what comes next. Join the fight with The CRA Union